H.C. Wainwright Assumes Aura Biosciences (AURA) at Buy

H.C. Wainwright analyst Andreas Maldonado assumes coverage on Aura Biosciences (NASDAQ: AURA) with a Buy rating and a price target of $22.00.

The analyst comments "Bel-sar’s progress in ocular oncology is just the beginning. Aura Biosciences is advancing a tumor-targeted platform that combines localized cytotoxicity with systemic immune activation, anchored by its proprietary virus-like drug conjugate (VDC) technology. With bel-sar, Aura is pioneering a mechanistically distinct class of therapeutics that can ablate solid tumors while preserving surrounding healthy tissue—an especially critical attribute in anatomically sensitive cancers like ocular melanoma. In choroidal melanoma, where enucleation and vision loss remain the clinical norm, bel-sar has demonstrated tumor control in up to 80% of treated patients and 90% vision preservation at 12 months. With a pivotal Phase 3 trial now enrolling under an SPA with the FDA, Aura is positioned to redefine the treatment paradigm in ocular oncology, where early intervention is often avoided due to the destructive nature of existing therapies. The company’s office-based workflow, repeatable dosing, and absence of systemic toxicity create a practical advantage for adoption among retina specialists. Hence, we assume coverage, with a Buy rating and $22 PT."

For an analyst ratings summary and ratings history on Aura Biosciences click here. For more ratings news on Aura Biosciences click here.

Shares of Aura Biosciences closed at $5.99 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Phillips 66, Marathon Merger Talks Collapsed - Semafor
• Aura Biosciences (AURA) PT Lowered to $18 at H.C. Wainwright